[Federal Register Volume 61, Number 243 (Tuesday, December 17, 1996)]
[Notices]
[Pages 66288-66289]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-31883]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for U.S. companies and may also be available for licensing.

ADDRESS: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804 (telephone 301/496-7057; fax 301/402-0220). A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

4'- and 4',4''-Substituted-3(diphenylmethoxy)tropane 
Analogs As Cocaine Therapeutics

AH Newman, AC Allen, RH Kline, S. Izenwasser, JL Katz (NIDA)
Serial No. 08/667,024 filed 20 Jun 96 (claiming benefit of 60/000,378 
filed 21 Jun 95)
Licensing Contact: Leopold J. Luberecki, Jr., 301/496-7735 ext. 223

    The invention provides a series of 4'- and 4',4''-substituted 
benztropine analogs that demonstrate high affinity binding (K1<30 
nM) to the dopamine transporter and bind selectively (>100-fold) over 
the other monoamine transporters. These compounds block dopamine 
reuptake in vitro and yet do not demonstrate a cocaine-like behavioral 
profile in animal models of psychomotor stimulant abuse. Structure-
Activity Relationships suggest that these compounds interact at a 
binding domain that differs from that of cocaine at the dopamine 
transporter. The invention also describes cocaine analogs comprising N-
substituted 2',3' and 3',3'' and 3',4''-analogs, which exhibit a 
cocaine-like behavioral profile. One of the compounds exhibits cocaine-
like activity and anti-muscarinic receptor activity, which may improve 
its therapeutic utility. These compounds represent an unprecedented 
class of dopamine uptake inhibitors that may have potential as cocaine-
abuse therapeutics, since they have neurochemical similarities to 
cocaine and yet do not appear to have abuse liability. Further, 
radiolabeled analogs will be suitable for imaging the dopamine 
transporter in mammalian brain using SPECT and PET and thus would be 
useful in the diagnoses and monitoring of neurodegenerative disorders 
involving the dopaminergic system (e.g., Parkinson's disease). In 
addition, the invention provides pharmaceutical compositions comprising 
an analog of the invention and a pharmaceutically acceptable carrier 
excipient. (portfolios: Central Nervous System--Therapeutics, 
psychotherapeutics, drug dependence; Central Nervous System--
Therapeutics, neurological, antiparkinsonian; Central Nervous System--
Diagnostics, in vivo)

Conjugate Vaccine For Nontypeable Haemophilus Influenzae

X-X Gu (NIDCD), C-M Tsai (CBER), DJ Lim (NIDCD), JB Robbins (NICHD)
Serial No. 60/016,020 filed 23 Apr 96
Licensing Contact: Elaine Gese, 301/496-7056 ext. 282


[[Page 66289]]


    This invention is a vaccine for the prevention of disease caused by 
nontypeable H. influenzae, which causes 25-40% of otitis media cases 
(middle ear infections) in children and other respiratory tract 
diseases in humans. The emergence of antibiotic-resistant bacteria has 
caused concern that treatment of otitis media will become more 
problematic. This invention offers a new approach to managing otitis 
media. The vaccine is composed of lipooligosaccharide, isolated from 
the surface of strains of nontypeable H. influenzae and treated with 
hydrazine to remove esterified fatty acids, covalently conjugated to an 
immunogenci carrier, such as tetanus toxoid. The conjugates have been 
shown to be nontoxic by the limulus amebocyte assay, rabbit pyrogen 
test, and in a mouse lethal toxicity test. Antisera raised in rabbits 
immunized with the conjugate is bactericidal. (portfolio: Infectious 
Diseases--Vaccines, bacterial)

Materials And Methods for Detection and Treatment of Insulin Dependent 
Diabetes

NK Maclaren, AL Notkins, Q Li, MS Lan (NIDR)
Serial No. 08/514,213 filed 11 Aug 95 and
Serial No. 08/548,159 filed 25 Oct 95
Licensing Contact: J. Peter Kim, 301/496-7056 ext. 264

    Insulin-dependent diabetes mellitus (IDDM) affects close to one 
million people in the United States. It is an autoimmune disease in 
which the immune system produces antibodies that attack the body's own 
insulin-manufacturing cells in the pancreas. Patients require daily 
injections of insulin to regulate blood sugar levels. The invention 
identified two proteins, named IA-2 and IA-2, that are 
important markers for type I (juvenile, insulin-dependent) diabetes. 
IA-2/IA-2, when used in diagnostic tests, recognized 
autoantibodies in 70 percent of IDDM patients. Combining IA-2/IA-
2 with other known markers increased the level of 
identification to 90 percent of individuals with IDDM. Moreover, the 
presence of autoantibodies to IA-2/IA-2 in otherwise normal 
individuals was highly predictive in identifying those at risk of 
ultimately developing clinical disease. It is now possible to develop a 
rapid and effective test that can screen large populations for IDDM. In 
addition, IA-2/IA-2 are candidates for immune tolerance and 
prevention of disease development.

Compositions Comprising Vitamin F

C Weinberger, S Kitareewan (NIEHS)
Serial No. 60/003,443 filed 08 Sep 95; PCT/US96/15205 filed 06 Sep 96
Licensing Contact: Carol Lavrich, 301/496-7056 ext. 287

    This invention relates to a collection of potential fat-soluble 
vitamins that may coordinate animal metabolism and development. RXR is 
a nuclear receptor that plays a central role in cell signaling by 
heterodimerizing with receptors binding thyroid hormones, retinoids and 
vitamin D. The invention and others of its compositions can be 
characterized as likely physiological effectors that may represent 
essential components for human nutrition and cell growth. Thus, the 
invention suggests that it may coordinate cell physiology through RXR-
dependent hormone signaling pathways.

Macrocyclic Chelates, And Methods of Use Thereof

OA Gansow, K Kumar (NCI)
Serial No. 08/140,714 filed 22 Oct 93
U.S. Patent 5,428,154 issued 27 Jul 95
Licensing Contact: Raphe Kantor, 301/496-7735 ext. 247

    Substituted 1,4,7,10-tetraaza cyclododecane-N,N', N'', N'''-
tetraacetic acid (DOTA) has numerous desirable chelating qualities that 
make it useful for treating a number of cdellular disorders. Presently 
available chelating agents lack specificity for their intended targets 
or do not adequately bind the chelated metal ion. These substituted 
DOTAs have a strong affinity for a number of metal ions. They can also 
be linked to biomolecules to form systems for delivering the chelated 
metal ion, which can be radiolabeled, to specific sites within a cell 
or organelle. (portfolio: Cancer--Therapeutics, immunoconjugates, 
conjugate chemistry)

The Cloning of Perilipin Proteins

C Londos, AS Greenberg, AR Kimmel, JJ Egan (NIDDK)
Serial No. 08/132,649 filed 04 Oct 93
U.S. Patent 5,585,462 to issue 17 Dec 96
Licensing Contact: Ken Hemby, 301/496/7735 ext. 265

    Perilipins are found at the surface of lipid storage droplets of 
adipocytes. Little is known about the molecules on the surface of lipid 
droplets that may be involved in lipid metabolism and trafficking. The 
present invention provides isolated nucleic acid sequences which encode 
a family of perilipin proteins as well as isolated, purified perilipin 
proteins. These are useful as markers for differentiation of true 
adipocyte cells from non-adipocyte cells which, as a result of 
pathophysiological conditions, assume adipocyte characteristics. 
(portfolio: Cancer--Research Materials)

    Dated: December 6, 1996.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 96-31883 Filed 12-16-96; 8:45 am]
BILLING CODE 4140-01-M